Abeona Therapeutics Inc. (ABEO)Healthcare | Biotechnology | Cleveland, United States | NasdaqCM
4.94 USD
-0.02
(-0.403%) ⇩
(Oct. 9, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:11 a.m. EDT
The investment case here is severely compromised by a deteriorating business model. The company is burning cash aggressively, with operating cash flow and free cash flow both deeply negative, while gross margins are negative, indicating that the cost of goods sold exceeds revenue. Despite a recent uptick in top-line growth, the underlying economics are broken. The balance sheet, while currently liquid, is not generating enough cash to sustain operations without constant capital raises, which dilutes shareholders. The stock has suffered a catastrophic long-term decline, losing nearly 97% of its value over the last decade, reflecting the market's loss of faith in the company's ability to execute or monetize its pipeline. The recent price action shows weakness, trading below key moving averages, confirming the lack of momentum. With no dividend to provide income and a high short interest suggesting skepticism among leveraged traders, the outlook remains bleak. The massive put option activity confirms that the market is pricing in further downside risk, making this a dangerous hold for any investor seeking capital preservation or growth. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.115369 |
| MSTL | 0.115472 |
| AutoETS | 0.115612 |
| AutoTheta | 0.167130 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 4.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.233 |
| Excess Kurtosis | -0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2000-03-30 |
| Debt to Equity Ratio | 15.518 |
| Revenue per Share | 0.457 |
| Market Cap | 282,489,056 |
| Forward P/E | -23.81 |
| Beta | 1.30 |
| Profit Margins | -246.42% |
| Website | https://www.abeonatherapeutics.com |
As of Oct. 10, 2026, 3:11 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts expiring in December 2026 and March 2027. While there is some call volume at strikes above the current price, the overwhelming majority of option activity is concentrated in put contracts, suggesting a bearish sentiment and a fear of further decline rather than a bullish expectation of a rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2000-03-31 | 3706.25 | 8.547748 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.086876154 |
| Address1 | 6,555 Carnegie Avenue |
| Address2 | 4th Floor |
| All Time High | 5,437,500.0 |
| All Time Low | 0.27 |
| Ask | 6.28 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,241,810 |
| Average Daily Volume3 Month | 1,385,160 |
| Average Volume | 1,385,160 |
| Average Volume10Days | 1,241,810 |
| Beta | 1.3 |
| Bid | 3.57 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 2.238 |
| City | Cleveland |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.94 |
| Current Ratio | 6.635 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,789,430,400 |
| Day High | 5.04 |
| Day Low | 4.885 |
| Debt To Equity | 15.518 |
| Display Name | Abeona Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,624,200 |
| Earnings Call Timestamp Start | 1,786,624,200 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -80,789,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.024 |
| Enterprise To Revenue | 6.408 |
| Enterprise Value | 163,540,800 |
| Eps Current Year | -0.95 |
| Eps Forward | -0.2075 |
| Eps Trailing Twelve Months | -1.18 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.8822 |
| Fifty Day Average Change | -0.9421997 |
| Fifty Day Average Change Percent | -0.16017812 |
| Fifty Two Week Change Percent | -8.687615 |
| Fifty Two Week High | 7.65 |
| Fifty Two Week High Change | -2.71 |
| Fifty Two Week High Change Percent | -0.35424837 |
| Fifty Two Week Low | 4.0 |
| Fifty Two Week Low Change | 0.94000006 |
| Fifty Two Week Low Change Percent | 0.23500001 |
| Fifty Two Week Range | 4.0 - 7.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 338,218,200,000 |
| Float Shares | 36,851,668 |
| Forward Eps | -0.2075 |
| Forward P E | -23.80723 |
| Free Cashflow | -73,398,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 226 |
| Fullday Change | -0.01999998 |
| Fullday Change Percent | -0.40322542 |
| Fullday Price | 4.94 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -0.39898 |
| Gross Profits | -10,182,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10963 |
| Held Percent Institutions | 0.74903 |
| Implied Shares Outstanding | 57,184,017 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.accesspharma.com/investor-relations/ |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 954,460,800 |
| Last Dividend Value | 3,706.25 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,656,979,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. |
| Long Name | Abeona Therapeutics Inc. |
| Market | us_market |
| Market Cap | 282,489,056 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_360935 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -62,887,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 316,227,614 |
| Number Of Analyst Opinions | 8 |
| Open | 4.94 |
| Operating Cashflow | -76,440,000 |
| Operating Margins | -1.1997399 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 646 813 4701 |
| Previous Close | 4.96 |
| Price Eps Current Year | -5.2000003 |
| Price Hint | 4 |
| Price To Book | 2.207328 |
| Price To Sales Trailing12 Months | 11.069321 |
| Profit Margins | -2.46422 |
| Quick Ratio | 6.318 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.01999998 |
| Regular Market Change Percent | -0.40322542 |
| Regular Market Day High | 5.04 |
| Regular Market Day Low | 4.885 |
| Regular Market Day Range | 4.885 - 5.04 |
| Regular Market Open | 4.94 |
| Regular Market Previous Close | 4.96 |
| Regular Market Price | 4.94 |
| Regular Market Time | 1,791,576,001 |
| Regular Market Volume | 1,284,908 |
| Return On Assets | -0.2455 |
| Return On Equity | -0.43127 |
| Revenue Growth | 27.45 |
| Revenue Per Share | 0.457 |
| Sand P52 Week Change | 0.17383456 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 57,184,017 |
| Shares Percent Shares Out | 0.2753 |
| Shares Short | 15,745,098 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 14,271,165 |
| Short Name | Abeona Therapeutics Inc. |
| Short Percent Of Float | 0.29549998 |
| Short Ratio | 12.95 |
| Source Interval | 15 |
| State | OH |
| Symbol | ABEO |
| Target High Price | 30.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 18.875 |
| Target Median Price | 17.0 |
| Total Cash | 146,826,000 |
| Total Cash Per Share | 2.568 |
| Total Debt | 19,872,000 |
| Total Revenue | 25,520,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.5487 |
| Two Hundred Day Average Change | -0.6086998 |
| Two Hundred Day Average Change Percent | -0.109701335 |
| Type Disp | Equity |
| Volume | 1,284,908 |
| Website | https://www.abeonatherapeutics.com |
| Zip | 44,103 |